Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
FDA issues warning against 'microdosing' chocolate bars that sent 6 to the hospital
FDA warns against Diamond Shruumz-brand microdosing chocolate bars after eight people in four states fell ill, with six hospitalized. Symptoms included seizures and CNS depression. The bars, marketed as microdoses, contain no psychedelics but a proprietary blend of natural ingredients. FDA investigates the cause.
Single dose of LSD provides immediate, lasting anxiety relief, study says
Mind Medicine Inc. announced FDA breakthrough therapy status for an LSD formulation, MM120, to treat generalized anxiety disorder, showing 48% remission at 12 weeks. The phase 2b trial highlighted significant clinical improvements without psychotherapy, marking a pivotal step in psychedelic treatment research.
Ohio boy fights rare disease, plus learn about prostate cancer myths and psychedelics for PTSD
Emily Blackburn seeks research and funds for her son's rare disease. Alzheimer's subgroups identified. Prostate cancer myths debunked. Caution urged on semaglutide overdoses. Winter lifestyle and driving safety tips. MDMA and magic mushrooms for PTSD treatment. Gourmet cooking gadgets. New leading cause of cancer deaths under 50. Etiquette on touching pregnant women's bellies.
Informed Consent to Psychedelic-Assisted Psychotherapy
Psychedelic-assisted psychotherapy (PAP) uses substances like psilocybin, LSD, and MDMA with therapy for conditions like PTSD and depression. It involves preparatory, medication, and integration sessions. Challenges include managing difficult experiences and ensuring informed consent, especially regarding session termination and therapeutic touch. Strategies to strengthen consent include psychiatric advance directives and dynamic consent, emphasizing trust and ethical considerations in PAP.
Drug batch fears after suspected overdoses at festival
Nine hospitalized after suspected drug overdoses at Melbourne's Hardmission festival, with eight initially critical. A bad batch of MDMA suspected. Calls for pill testing at festivals to prevent future incidents, amidst government opposition to such measures.
Combat veterans took a psychedelic drug for PTSD. Then this happened.
Herb Daniels, a former Green Beret with PTSD and traumatic brain injury, found hope through ibogaine, a psychedelic treatment in Mexico. A Stanford study with 30 veterans showed significant improvements in PTSD, depression, anxiety, and cognitive functions post-treatment. Despite promising results, more research is needed to confirm ibogaine's efficacy and safety for broader use.
Weight loss, drug prices, abortion and prescribed psychedelics anticipate major health care developments in 2024
2024 anticipates major health care developments: effective weight-loss drugs like Wegovy and Zepbound become more accessible; psychedelics like MDMA and psilocybin gain traction for mental health treatment; new drug price limits under the Inflation Reduction Act may lower costs; and the Supreme Court's decision on mifepristone could impact abortion access.
Johns Hopkins experts discuss the promise and pitfalls in psychedelics research
Johns Hopkins leads in psychedelics research, showing potential in treating mental health conditions with substances like psilocybin, MDMA, and DMT. Despite therapeutic promise, legal and public perception hurdles persist. Research suggests psychedelics could revolutionize treatment, offering rapid, cost-effective solutions without addiction risks, pending further study and policy changes.
New Research Exploring Psychedelics as a Treatment for Anxiety in Cancer Patients
Psychedelics like psilocybin and MDMA show promise in treating mental health conditions, including anxiety and depression in cancer patients, with studies highlighting their potential for long-lasting effects. However, further research is needed to confirm safety and efficacy, and treatments are conducted in controlled environments with therapeutic support.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath